Bishal Gyawali/scri.queensu.ca
Jan 27, 2025, 08:52
Bishal Gyawali: Why Overall Survival Should Be The Oncology Trial Endpoint
Bishal Gyawali, Associate Professor at Queen’s University, shared a post on LinkedIn:
“Every time they approve a drug based on non-survival endpoint, they give us some excuse.
I have collected those excuses. There are seven of them. In this new column in Medscape , I and Dr. Sharon Batt, a cancer survivor and regulatory science expert, list these seven arguments and specifically respond to each of them to demonstrate why OS still remains the most patient centric endpoint for cancer drug trials.
Please do read.
This is NOT another “surrogates are bad” paper.
We specifically address the concerns raised against OS.
I hope you’ll be convinced.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 25, 2025, 11:24
Feb 25, 2025, 11:23
Feb 25, 2025, 11:17
Feb 25, 2025, 11:15
Feb 25, 2025, 11:11
Feb 25, 2025, 11:04
Feb 25, 2025, 11:03
Feb 25, 2025, 10:56
Feb 25, 2025, 10:52
Feb 25, 2025, 10:52
Feb 25, 2025, 10:45